Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 2, 1999, Pages 143-151

  Gurnani, Maya ^a   Lipari, Philip ^a   Dell, Janet ^a   Shi, Bin ^a   Nielsen, Loretta L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

5 Fluorouracil; Cisplatin; Doxorubicin; Etoposide; Methotrexate; p53 adenovirus; p53 gene therapy; Paclitaxel

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; PACLITAXEL;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; GENE THERAPY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DNA DAMAGE; FEMALE; GENE THERAPY; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICE; MICE, INBRED ICR; MICE, SCID; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS;

EID: 0032990031     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050959     Document Type: Article

References (42)

1. 1. Bartek J, Iggo R, Gannon J, Lane DP (1990) Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5: 893
2. 2. Blagosklonny M, El-Diery WS (1996) In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int J Cancer 67: 386
3. 3. Blagosklonny MV, El-Diery WS (1998) Acute overexpression of WT p53 facilitates anticancer drug-induced death of cancer and normal cells. Int J Cancer 75: 933
4. 4. Caamano J, Zhang SY, Rosvold EA, Bauer B, Klein-Szanto AJP (1993) p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am J Pathol 142: 1131
5. 5. Chang EH, Jang YJ, Hao Z, Murphy G, Rait A, Fee WE, Sussman HH, Ryan P, Chiang Y, Pirollo KF (1997) Restoration of the G1 checkpoint and the apoptotic pathway mediated by wild-type p53 sensitizes squamous cell carcinoma of the head and neck to radiotherapy. Arch Otolaryngol Head Neck Surg 123: 507
6. 6. Donaldson KL, Goolsby GL, Wahl AF (1994) Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer 57: 847
7. 7. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215
8. 8. Dorigo O, Turla ST, Lebedeva S, Gjerset RA (1998) Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function. J Neurosurg 88: 535
9. 9. Dorr RT, Von Hoff DD (1994) Cancer chemotherapy handbook. Appleton & Lange, Norwalk
10. 10. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang W-W, Owen-Schaub LB, Roth JA (1994) Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54: 2287
11. 11. Gallardo D, Drazan KE, McBride WH (1996) Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res 56: 4891
12. 12. Gjerset RA, Turla ST, Sobol RE, Scalise JJ, Mercola D, Collins H, Hopkins PJ (1995) Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog 14: 275
13. 13. Harris MP, Sutjipto S, Wills KN, Hancock W, Cornell D, Johnson DE, Gregory RJ, Shepard HM, Maneval DC (1996) Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther 3: 121
14. 14. Horwitz SB (1992) Mechanism of action of taxol. Trends Pharmacol Sci 13: 134
15. 15. Huyghe BG, Liu X, Sutjipto S, Sugarman BJ, Horn MT, Shepard H, Scandella CJ, Shabram P (1995) Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum Gene Ther 6: 1403
16. 16. Isaacs WB, Carter RS, Ewing CM (1991) Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51: 4716
17. 17. Jung M, Notario V, Dritschilo A (1992) Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res 52: 6390
18. 18. Lowe SW (1995) Cancer therapy and p53. Curr Opin Oncol 7: 547
19. 19. McGovern JP (1994) Pharmacologic principles. In: Dorr RT, Von Hoff DD (eds) Cancer chemotherapy handbook. Appleton & Lange, Norwalk, pp 15-34
20. 20. Min B, Baek J, Shin K, Gujuluva CN, Cherrick HM, Park N (1994) Inactivation of the p53 gene by either mutation or HPV infection is extremely frequent in human oral squamous cell carcinoma cell lines. Oral Oncol Eur J Cancer 30B: 338
21. 21. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 64: 55
22. 22. Musco ML, Cui S, Small D, Nodelman M, Sugarman B, Grace M (1998) A comparison of flow cytometry and laser scanning cytometry for the intracellular evaluation of adenoviral infectivity and p53 protein expression in gene therapy. Cytometry 33: 290
23. 23. Nielsen LL, Maneval D (1998) p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 5: 52
24. 24. Nielsen LL, Dell J, Maxwell E, Armstrong L, Maneval DC, Catino J (1997) Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther 4: 129
25. 25. Nielsen LL, Lipari P, Dell J, Gurnani M, Hajian G (1998) Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin Cancer Res 4: 835
26. 26. Nielsen LL, Gurnani M, Syed J, Dell J, Hartman B, Cartwright M, Johnson RC (1998) Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in mouse tumor xenograft models. Hum Gene Ther 9: 681
27. 27. Meisen LL, Gurnani M, Dell J, Maneval DC, Zepeda M (1998) Immune modulation of the host response to p53 adenovirus. Proc Am Assoc Cancer Res 39: 514
28. 28. Nguyen DM, Spritz FR, Yen N, Cristiano RJ, Roth JA (1996) Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 112: 1372
29. 29. Ogawa N, Fujiwara T, Kagawa S, Nishizaki M, Morimoto Y, Tanida T, Hizuta A, Yasuda T, Roth JA, Tanaka N (1997) Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. Int J Cancer 73: 367
30. 30. Ozbun MA, Butel JS (1995) Tumor suppressor p53 mutations and breast cancer: a critical analysis. Adv Cancer Res 66: 71
31. 31. Ozols RF, Vermorken JB (1997) Chemotherapy of advanced ovarian cancer: current status and future directions. Semin Oncol 24 [Suppl. 2]: S2-1-S2-9
32. 32. Pirollo K-F, Hao Z, Rait A, Jang Y, Fee WE, Ryan P, Chiang Y, Chang E (1997) p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 14: 1735
33. 33. Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247
34. 34. Selter H, Montenarh M (1994) The emerging picture of p53. Int J Biochem 26: 145
35. 35. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ, Roth JA (1996) Adenoviral-mediated wildtype p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 2: 1665
36. 36. Thompson CB (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456
37. 37. Vasey PA, Jones NA, Jenkins S, Dive C, Brown R (1996) Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharrnacol 50: 1536
38. 38. Wahl AF, Donaldson KL, Fairchild C, Lee FYF, Foster SA, Deniers GW, Galloway DA (1996) Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat Med 2: 72
39. 39. Wills KN, Maneval DC, Menzel P, Harris MP, Sutjipto S, Vaillancourt M-T, Huang W-M, Johnson DE, Anderson SC, Wen SF, Bookstein R, Sherpard HM, Gregory RJ (1994) Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 5: 1079
40. 40. Yaginuma Y, Westphal H (1992) Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 52: 4196
41. 41. Yang B, Eshleman, JR, Berger NA, Markowitz SD (1996) Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 2: 1649
42. 42. Yang Y, Nunes FA, Berencsi K, Furth EE, Gomczol E, Wilson JM (1994) Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91: 4407